key: cord-0287675-h0n4lig0
authors: Erster, O.; Mendelson, E.; Kabat, A.; Levy, V.; Mannasse, B.; Asraf, H.; Azar, R.; Ali, Y.; Bucris, E.; Bar-Ilan, D.; Mor, O.; Elul, M.; Mandelboim, M.; Sofer, D.; Fleishon, S.; Zuckerman, N. S.; Bar-Or, I.
title: SPECIFIC DETECTION OF SARS-COV-2 VARIANTS B.1.1.7 (ALPHA) AND B.1.617.2 (DELTA) USING A ONE-STEP QUANTITATIVE PCR ASSAY
date: 2021-10-14
journal: nan
DOI: 10.1101/2021.10.11.21264831
sha: 39f73b61f9275925313617984ce45abb6ec554b2
doc_id: 287675
cord_uid: h0n4lig0

In this report, we describe the development of an RT-qPCR assay, termed Alpha Delta assay, which can detect SARS-COV-2 (SC-2) and distinguish between the Alpha (B.1.1.7) and Delta (B.1.617.2) variants. The Alpha- and Delta-specific reactions in the assay target mutations that are strongly linked to the target variant. The Alpha reaction targets the D3L substitution in N gene, and the Delta reaction targets the spike gene 156-158 mutations. Additionally, we describe a second Delta-specific assay that we use as a confirmatory test for the Alpha Delta assay that targets the 119-120 deletion in the Orf8 gene. Both reactions have similar sensitivities of 15-25 copies per reaction, similar to the sensitivity of commercial SC-2 detection tests. The Alpha Delta assay and the Orf8-119del assay were successfully used to classify clinical samples that were subsequently analyzed by whole genome sequencing. Lastly, the capability of the Alpha Delta assay and Orf8-119del assay to identify correctly the presence of Delta RNA in wastewater samples was demonstrated. This study provides a rapid, sensitive and cost-effective tool for detecting and classifying two worldwide dominant SC-2 variants. It also highlights the importance of a timely diagnostic response to the emergence of new SC-2 variants with significant consequences on global health.

The emergence of new SC-2 variants has been a major concern due to their potential to increase morbidity and mortality, thereby causing further difficulty in fighting and containing the worldwide COVID19 pandemic (Davies et al. 2021 ,Mlcochova et al. 2021 . Since the end of 2020, more than 20 SC-2 variants with distinct genomic signature have been identified worldwide, some of these variants divided into additional subclades (https://covariants.org/, https://covlineages.org/lineage_list.html). Some of them were characterized by markedly increased infectivity, which led to recurring outbreaks and "take-over" effect of specific variants, such as B.1.1.7 (Alpha) in a matter of 4-5 weeks (Davies et al. 2021) . Other variants, such as B.1.351 (Beta) and P1 (Gamma) spread rapidly and showed a significant potential to become dominant (Chakraborty et al. 2021 ), but were eventually pushed aside by others. Variant B.1.617, initially identified in India on late 2020, spread rapidly and one of its sub-lineages-B.1.617-2 became a globally dominant variant within a few months. The transmission pattern of Alpha and Delta variants suggests that they both spread from their country of origin, rapidly reaching North and South America, Europe, Africa and Australia (Chakraborty et al. 2021) . In Israel, two large morbidity waves were associated with the introduction of new variants. First, the Alpha variant high morbidity wave, which started in mid-December 2020 and declined by mid-March 2021 following the successful nation-wide immunization campaign with two doses of the BNT162-b2 vaccine (Rossman et al. 2021) . Then, the current high morbidity wave dominated by the Delta variant, which started in July 2021 in parallel to vaccines waning immunity, and continues ( Bar-On et al. 2021) . Immunological studies demonstrated that some of the emerging variants have the potential to evade, at least partially, the neutralizing effect of both convalescent patients and vaccinated individuals (Cele et al. 2021 , Lustig Zhou et al. 2021 , Mlcochova et al. 2021 . The spreading of such variants my therefore compromise the effectiveness of global vaccination efforts, aimed to contain the COVID19 pandemic.

A fundamental pillar of the campaign against COVID19 is the ability to detect the presence and identity of SC-2 RNA in both infected individuals and environmental samples. This pressing need led to an unprecedented number of commercial detection kits based on molecular and serological principles, with varying degrees of sensitivity, throughput, reliability and turnaround time (Qasem et al. 2021 , Graham et al. 2021 , Pavia et al. 2021 . Due to their epidemiological and medical importance, the rapid identification of circulating variants becomes a central tool in the fight against the pandemic.

In addition to diagnosis of clinical samples, the monitoring of SC-2 RNA in environmental samples, mostly, but not exclusively, wastewater, proved as an important tool (Randazzo et al. 2020 , Ahmed et al. 2020 , Bar-Or et al. 2021 . Detection of SC-2 RNA in such samples is exceptionally challenging due to their very low abundance and the presence of PCR inhibitors, which render this approach even more difficult. Several reports describe the successful identification of SC-2 RNA in environmental samples, and some describe the classification of the examined samples, using sequencing (Yaniv doi.org/10.1016 /j.envres.2021 .111653, Goldin et al. 2021 , Bar-Or et al. 2021 ).

Classification of samples using sequencing requires sufficient quality and quantity, which are often not available, with environmental samples. Moreover, this approach is currently much more expensive compared with PCR-based assays, and cannot be scaled-up readily, to facilitate rapid screening of a large number of samples efficiently.

In order to address the need for rapid classification of SC-2 positive samples, several manufacturers released sets of molecular tests that specifically detect key mutations that are associated with increased transmissibility or vaccine resistance (www.seegene.com, www.thermofisher.com, www.kogene.co.kr). However, most of these mutations are common to multiple variants and therefore cannot be used to assign a sample of interest to a certain lineage with high degree of confidence using a single test. We recently developed quantitative PCR (qPCR)-based molecular tests that target mutations that are strongly associated with variants Alpha and Beta, thereby enabling rapid classification of such samples, with high confidence. We demonstrated that the selected target mutations successfully reflect the lineage of the examined sample, as confirmed by Sanger and whole genome sequencing (Erster et al. 2021) . In this report, we describe the development and utilization of two qPCR reactions that target mutations that are, thus far, unique to variant B.1.617 (Delta lineage). We combined one of these reactions with the N D3L reaction that detects the Alpha variant, and the inclusive E-sarbeco reaction (Corman et al. 2020) we described previously, to a new selective multiplex assay. This assay can determine if the examined samples is of lineage Alpha, Delta, or none of them. We show that the new multiplex assay, which we term "Alpha Delta assay", is rapid, sensitive and reliable, as confirmed by sequencing. Finally, we demonstrate the capability of the new assay to detect and classify SC-2 RNA extracted from environmental samples.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Clinical samples were prepared during the laboratory diagnostic routine from nasopharyngeal swabs, as described before (Erster et al. 2021) . RNA was extracted using either MagNA-Pure 96 system (Roche, https:// lifescience.roche.com/) or PPS MagLEAD system (http://www.pss.co.jp/english/ ). The extractions were used for routine clinical diagnostics and were incubated at -80°C for long-term storage prior to the novel assay development. Environmental samples were processed as described before (Bar-Or et al. 2021) . Briefly, sewage samples were centrifuged and filtered before extraction was commenced with either Nuclisense EasyMag (Biomerieux, https://www.biomerieuxusa.com/clinical/) or EMag extraction systems. Immediately after extraction, all samples were preserved at -80°C until PCR testing was performed.

In order to culture positive SC-2 samples, the medium from the selected collection tubes was filtered using a 0.22µM filter (https://www.merckmillipore.com/) and used for inoculation of Vero E6 cells.

The cells were allowed to reach 70% confluence and were then incubated for 1 hour at 37°C with 300µl of the filtered medium. After 1 hour, the medium was removed and the cells were incubated in MEM-EAGLE medium with 2% FCS. Cells were monitored daily for the presence of cytopathic effect (CPE). Upon CPE onset, the culture medium was collected and viral RNA was extracted. Resulting RNA extractions were kept at -80°C until use.

Sequences classified as B.1.617 were obtained from the GISAID database (https://www.epicov.org/epi3/frontend#2d1c1e) and were analyzed by alignment with reference sequence NC_045512 to identify mutated regions that can be used for differential analysis.

Uniqueness of the selected mutations was confirmed by performing global analysis for the selected mutations in the NextStrain website, to identify other lineages with identical mutations (https://nextstrain.org/ncov/gisaid/global). Corresponding primers and probes that detect only the mutated sequences were designed for each region, and examined In silico for secondary structure formation, specificity and compatibility with qPCR assay using the Geneious software (https://www.geneious.com/) and using the NCBI BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi).

The primers and probes used in this study are detailed in Table 1 .

MDX106 Inhibitor-tolerant RT-qPCR mix was from Bioline (Bioline, https://www.bioline.com/).

Primers and probes were either from Metabion (https://www.metabion.com/) or from Merk-Sigma is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Israel (https://www.sigmaaldrich.com/IL/en). Reaction components were assembled as described in Table 2 , using the MDX106 Inhibitor-tolerant mix. The reactions were run in CFX-96 thermal cycler (Bio-Rad, https://www.bio-rad.com/), using the following profile: 45°C for 10'10", 45X[ 95°C for 2'20", 95°C for 4", 60°C for 22"]. Fluorescence was recorded at 60°C, at the end of each amplification cycle. Results were analyzed using the CFX Maestro software (Bio-Rad).

The N-terminal domain (NTD) of the SC-2 Spike gene and the C-terminal domin (CTD) of SC-2 Orf8 were amplified using the primer pairs detailed in Table 1 . Primer pair T7-21494 Fwd + Cov19 22475 were used for the Spike region amplification, and primer pair pT7 27945 Fwd + 28525 Rev were used for the Orf8 region amplification. PCR was performed using the PCRBIO 1-Step Go RT-PCR Kit (https://pcrbio.com/row/products/pcr/pcrbio-1-step-go-rt-pcr-kit/) according to the manufacturer's instructions. The PCR products were resolved in 1.2% agarose gel electrophoresis to confirm adequate amplification. Each product was then used as template for dye labeling reaction using the BigDye kit (https://www.thermofisher.com/) according to the manufacturer's instructions.

Sequencing was performed using the ABI 3500 genetic analyzer (https://www.thermofisher.com/).

RNA standards of the reaction targets were designed and synthesized as described before (Erster et al. 2021) . The primers for the amplification of the S 157del and Orf8 119del reaction targets are detailed in Table 1 . RT-PCR was performed with Fwd primers containing the minimal T7 promoter sequence.

Resulting PCR products were purified using the Machery-Nagel NucleoSpin Gel and PCR Clean-up kit according to the manufacturer's instructions (https://www.mn-net.com/). The purified products were then used for In vitro transcription with the T7-Megascript kit according to the manufacturer's instructions (Thermo Fisher, https://www.thermofisher.com/). The concentration of the resulting RNA was measured using the NanoDrop spectrophotometer (https://www.thermofisher.com/il/en/). All reaction products were kept at -80°C until use.

In order to facilitate rapid classification of the examined sample, four reactions were combined in a single assay, as follows: the inclusive E-sarbeco, which detects SC-2 RNA regardless of the variant (FAM fluorophore), N D3L reaction, which detects the Alpha variant (HEX channel), S 157del reaction, which detects the Delta variant (TexasRed Channel), and an endogenous control reaction for the . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264831 doi: medRxiv preprint human RNAse P gene (Cy5 channel). The details of the E, N D3L and RNAse P reactions were described previously (Erster et al. 2021) . The combined multiplex was termed Alph-Delta assay hereafter. The analytical sensitivity of the Alph-Delta assay was evaluated using serial dilutions of the In-vitro transcribed targets of each reaction. All four targets were mixed together in an initial concentration of 10 -4 ng/µl, and 10-fold dilutions were prepared in nuclease-free TE buffer pH7.5 (IDT, https://eu.idtdna.com/). The clinical sensitivity was evaluated by serially diluting positive samples in an extraction of a SC-2 -negative sample.

Wastewater collection was based on composite automated sampler for 24 hour located in different wastewater treatment plants. The samples were transfered under cold conditions to the lab and were processed within 24 hours. Concentration process uses 20 ml of raw sewage in duplicates. The raw sewage was centrifuged at 4700g for 5 min. The supernatant was transferred to a new tube containing 0.5gr MgCl 2 (0.26M). The tube was gently shaked for 5 min and then filtered through 0.45μm pore-size, 47-mm diameter electronegative MCE membranes (Merck Millipore Ltd). The membrane was immediately transferred to a new tube containing 3 ml of lysis buffer (NucliSENS easyMAG). The tube was gently shaked to extract the trapped RNA virus. Total nucleic acids (NA) were extracted using the NucliSENS easyMAG system (bioM‫י‬rieux, Marcyl'Etoile, France) according to the manufacturer's instructions. Extracted NA were eluted in 55 μl elution buffer and stored at −70 °C until sequencing.

COVID-seq kit was used for library preparation as per manufacturer's instructions (Illumina, https://www.illumina.com). Library validation and mean fragment size was determined by tapestation 4200 via DNA HS D1000 kit (Agilent, https://www.agilent.com/). Libraries were pooled, denatured and diluted to 10pM and sequenced on NovaSeq system (Illumina).

Alignment of genomes identified as the Delta lineage from the GISAID database (https://www.gisaid.org/) with SC-2 reference sequence NC_045512 showed that all Delta sequences contained a substitution in position deletion in positions 22045-22050, which translates into a.a. E to . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264831 doi: medRxiv preprint G substitution in position 156 and deletion in positions 157-158 in the Spike protein ( Figure 1A) .

Accordingly, a specific reaction was designed to detect that deletion, denoted S 157del reaction hereafter, by using a probe that can only bind to the mutated sequence (21987 probe). In order to establish that the selected mutations were indeed unique to the Delta lineage, global analysis of SC-2 genomes was performed using the NextStrain website (https://nextstrain.org/), using the deletion in positions 22045-22050 as a search term. The resulting dendrogram showed that the double deletion was indeed unique to the Delta lineage and was absent from other known lineages (Supplementary Figure 1A) .

The Delta genomes alignment showed a second unique deletion, mapped to nucleotide positions 28248-28253 in reference sequence NC_045512C, at the C-terminal end of Orf8, spanning amino acids 119-120 of the protein (Figure 2A) . Global genome analysis performed as described for the 22045-22050 deletion, showed that the deletion at positions 28248-28253 was also unique for Delta lineage ( Figure 2B) . A specific probe was designed to identify the deletion-containing sequence (28199). Secondary structure simulation suggested that the original probe sequence is likely to generate a strong stem-loop structure, thereby significantly reducing the reaction efficiency.in order to avoid this undesired outcome, a single G to T substitution was incorporated at position 10, in order to avoid the stem-loop formation (Supplementary Figure S1) . Two primers were then designed to amplify the deletion region and complete the RT-qPCR assay. The sequences of the Orf8 119-120del primers and probe are detailed in Table 1 . Sequencing of the C-terminal domain (CTD) of the Orf8 gene from the same four samples classified by the S 157del assay as Delta, confirmed the presence of the Orf8 119-120 deletion, which is the target of the Orf8 119del reaction ( Figure 2B ). Additional confirmation for the accuracy of the two reactions was performed by sequencing four samples that were identified as Delta-suspected. Each sample was sequenced in the S 157del region and the Orf8 119del region. As shown in Supplementary Figure S2 , all sample contained both deletions.

In order to facilitate detection of SC-2 RNA regardless of the lineage and identify the Alpha or Delta lineages in a single test, the three reactions were combined in one multiplex termed "Alpha-Delta assay". A control reaction detecting human RNAseP gene was also included in the multiplex for an endogenous control, as was performed previously (doi.org/10.1101/2021.05.19. 21257439).

Analytical sensitivity of the Alpha-Delta assay was evaluated using serial dilutions of mixed RNA targets of the four reactions combined in the assay. Each dilution was examined in a triplicate. The limit of detection (LOD) for the SC-2 targets was determined to be 33.3 copies/reaction for the Esarbeco reaction, 12.9 copies for the N D3L reaction, and 14.5 copies for the S 157del reaction. The LOD . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264831 doi: medRxiv preprint for the hRNAse P reaction was 35.4 copies/reaction (Supplementary Figure S3) . The Orf8 119del reaction was developed as a confirmatory assay for inconclusive Delta suspected samples. This reaction was used in combination with the E-sarbeco reaction that served as an inclusive SC-2 control reaction to ensure the presence of the SC-2 RNA. The analytical LOD of that reaction was determined to be 23.6 copies/reaction (Supplementary figure S3) . The specificity of the Delta-specific reactions was tested using RNA extractions from lineages 19A/19B (Wuhan lineage), Alpha, Beta and Gamma.

As detailed in Supplementary Table S1, all lineages were negative for both the S 157del and Orf8 119del reactions.

Analysis of the amplification curves of the different Delta assay variations showed that in some samples, mostly with a high RNA concentration (Cq≤22), a weak signal in the HEX channel was observed, assumingly resulting from low-affinity N D3L reaction ( Figure 3D ). However, in these cases, the Cq values of the E-sarbeco reaction and the S 257del reaction (in Delta samples) were always at least 10 cycles earlier than that of the N D3L reaction, thereby clearly indicating that the sample was not of the Alpha lineage. Both the S 157del and the Orf8 119del reactions were very specific and did not give a positive signal in non-Delta samples (Figure 3) . In order to determine a possible mutual effect of the four reactions combined together, serial dilutions of Delta RNA from cultured cells were tested, showing similar sensitivity of both the E-sarbeco and S 157del reactions, thus confirming the maintained sensitivity of the Alpha-Delta multiplex (Supplementary figure S4) .

Between January and May 2021, the prevalent lineage in Israel was Alpha. The Delta lineage began spreading in the country during mid-June 2021. The Alpha-Delta assay was therefore used to classify clinical samples whose lineage attribution was unknown, in order to enable rapid epidemiological investigations and to aid decision making regarding whole genome sequencing (WGS) prioritization.

Later on, it was used as a routine test at the Israel Central Virology Laboratory. During June-August 2021, over 1,400 clinical samples were classified as Delta, Alpha or neither, using this assay. This classification was subsequently confirmed by Illumina WGS analysis. The details of 62 such samples selected randomly are listed in Tables 3 and 4. All samples classified by the Alpha-Delta qPCR assay as suspected Delta, were either identified as such by the WGS analysis, or classified as "no lineage" (Table 3) . Those who were designated "no lineage" were mostly with Cq value higher than 32, and were all with 70% or less sequencing coverage (Table 4 ). These samples, which were classified as "Delta-suspected" by the Alpha-Delta assay, were positive for the Orf8 119-120 deletion, but the S 157del region was not fully sequenced. Comparison of the PCR results with the Illumina WGS analysis showed that of the 62 samples randomly selected, 19 were not classified by the WGS analysis, but . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10. 1101 were positive for the Delta-specific deletions, either the S157 del or the Orf8 119del , or both ( Table 3) .

Examination of the Cq values obtained for the WGS non-classified samples, showed that two samples had values of 27 and 29 (14957 and 14968, respectively), and all others were higher than 30 ( Table   3 ). The sequence coverage of the unclassified samples ranged between 20.9% and 70% (Table 4) .

These data suggest that the positive identification of both the Orf8 119del and the S 157del mutations by the qPCR assay, enable a more definite classification of these samples, even in the absence of a complete sequencing coverage. The assay also detected a small number of Alpha lineage samples (two in the samples presented in Tables 3, 4) , where the N D3L mutation was detected by both the qPCR assay and the WGS analysis (Tables 3, 4) .

The capability of the Alpha-Delta and confirmatory Orf8 119del assays to detect the presence of the Delta lineage RNA in sewage samples was evaluated using samples from different periods, before and after the Delta outbreak in Israel, in mid-June 2021. As detailed in Table 5 , the assay correctly identified the samples from 2020 as non-Alpha, non-Delta, while samples from July 2021 were identified as Delta lineage. The Cq values of the S 157del reaction were comparable to those of the Esarbeco reaction, demonstrating sufficient sensitivity of that reaction with RNA extraction of wastewater. These results demonstrate the capability of the Alpha-Delta assay to detect the presence of SC-2 in wastewater and determine whether the Alpha or Delta lineages, or both, are circulating in the examined regions. Examination of the recent samples from July 2021 using the confirmatory ORF8 119del reaction showed that all samples were identified as positive for the mutation. Six samples from 2020 were re-tested using the ORF8 119del reaction and were negative for the presence of the ORF8 119del mutation ( Table 5) . Although the Cq values obtained with the ORF8 119del reaction were 2-3 cycles higher than those of the S 157del reaction in this test, all samples were correctly identified. Collectively, these results show that both the Alpha-Delta multiplex and the confirmatory ORF8 119del test are valid assays for examination of wastewater samples for the presence of the Delta lineage.

The emergence of SC-2 variants that have the potential to affect both COVID-19 spreading and vaccine evasion, poses additional challenge for current intensive diagnostics efforts worldwide. The is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264831 doi: medRxiv preprint primary goal of diagnostic SC-2 tests was initially to detect the presence of SC-2 RNA, either in clinical or environmental samples. However, the need for rapid classification of SC-2 sample for their lineage, once a sample is determined as SC-2 positive, becomes essential, when attempting to monitor emergence or incursion of new variants, into a country, a geographic region, or a community. Surveillance through sequencing is probably the ultimate tool to identify the emergence of new and potentially important variants (Robishaw et al. 2021) . However, whole genome sequencing (WGS) is expensive, time-consuming, required exceptionally skilled personnel and cannot be readily scaled-up for high throughput testing, compared to rapid molecular tests (Goldin et al. 2021 , van Dorp et al. 2020 . In this dynamic situation of emerging variants, rapid, cost-effective and high throughput identification of circulating SC-2 variants is required.

We recently reported on the development and utilization of a rapid multiplex RT-qPCR assay that successfully classified SC-2 samples as Alpha or Beta, or neither. We demonstrated that it could be readily scaled-up to accommodate high throughput testing (Erster et al. 2021 ). Here, we describe a new assay that combines general detection of SC-2, together with specific classification of the two major variants Alpha and Delta. Previous reports of in-house selective assays, as well as commercial variant detection kits, rely mostly on the identification of common mutations that are not specific to a single variant (Migueres et al. 2021 , Lu et al. 2021 , Zelyas et al. 2021 . Other VOC detection approaches rely on multi-step expensive procedures , Tierling et al. 2021 . Such assays are not suitable for rapid determination the identity of an examined sample, based on a single assay. Confirmation of the Alpha Delta assay results by Sanger and Illumina sequencing reinforced its importance as a first line rapid and reliable tool for classification of major VOCs, obviating the need for further examination. The identification of both Orf8 and Spike gene Delta-specific deletions, in samples with insufficient sequencing coverage, demonstrated the usefulness of the Alpha Delta assay, in determining the identity of "sequencing-resistant" samples. Such problems can result from low RNA quantity (as evident by the Cq values detailed in Table 3 ), or other factors preventing the completion of the sequencing procedure. This is particularly important in classification of wastewater-derived samples, where the target RNA is a pool from multiple individuals, is diluted and the sample contains chemical inhibitors. The Alpha Delta assay successfully detected the presence of the Delta variant even in very low RNA concentration, thereby enabling sensitive monitoring of the circulation of this variant during its incursion into the country. This assay was also used for screening international arrivals, which is particularly important when attempting to prevent the spreading of new variants. While other reported approaches to detect SC-2 variants in international travelers rely on lengthy multi-step procedures (Tierling et al. 2021 this assay is rapid (~80 minutes from extraction to answer) and can be implemented in most standard laboratories that . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 perform routine PCR tests. This is particularly advantageous when an accelerated epidemiological investigation or other actions need to be taken, and complete genomic analysis is not available.

The Orf8 119del reaction was used in this study as a confirmatory assay, complementing the first-line Alpha Delta assay. This is useful to confirm ambiguous results, and to provide additional support for lineage classification, when sequencing analysis is not available. The S 157del and the Orf8 119del reactions showed similar performance in both clinical and wastewater samples and are therefore equally useful in the current situation where both deletions are unique for the Delta variant. However, if a new variant will emerge, where one of these mutations is present, re-assessment of the multiplex combination can be performed, in order to adjust the reactions to the required assay specificity. The ability to assemble different reactions into a single multiplex assay is advantageous with respect to the intended use of the assay, as we show here. When the Beta variant was introduced in Israel, we used the combination of the Alpha Beta and inclusive E reactions to classify the examined samples.

Upon introduction of the Delta variant, we modified the assay and added a confirmatory reaction, to accommodate the pressing need to identify the Delta and Alpha variants, but also identify non-Alpha, non-Delta positive samples, all in a single 80-minutes standard RT-qPCR assay.

This study therefore demonstrates that in addition to implementation of a useful diagnostic tool, the approach of a developing tailor-made variant-specific qPCR assay can improve the SC-2 diagnostic capability in any qPCR-qualified laboratory, and can complement variant classification when WGS analysis either fails or is not available. Furthermore, such an assay can be valuable for epidemiological studies, enabling a quick and affordable assessment of the circulation of major variants in a community, or in a geographic region of interest. It is conceivable that the emergence of future SC-2 variants, and possibly other infectious viruses, will warrant further development of such diagnostic tools. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the Sheba Medical Center institutional review board (7045-20-SMC). For the Israel cohort, patient consent was waived as the study used remains of clinical samples and the analysis used anonymous clinical data.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264831 doi: medRxiv preprint Minimal T7 promoter sequence is in bolded letters . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264831 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264831 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264831 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264831 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264831 doi: medRxiv preprint 

First confirmed detection of SARS-CoV-2 in untreated wastewater in Australia: A proof of concept for the wastewater surveillance of COVID-19 in the community

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Detection of SARS-CoV-2 variants by genomic analysis of wastewater samples in Israel

Network for Genomic Surveillance in South Africa; COMMIT-KZN Team, Lessells RJ, de Oliveira T, Sigal A. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Evolution, mode of transmission, and mutational landscape of newly emerging SARS-CoV-2 variants

Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Antibody evasion by the P.1 strain of SARS-CoV-2. Cell

Rapid And high throughput RT-qPCR assay for identification and differentiation between SARS-CoV-2 variants B.1.1.7 and B.1.35. medRxiv

Use of emerging testing technologies and approaches for SARS-CoV-2: review of literature and global experience in an Australian context

Next-Generation Sequencing (NGS) in COVID-19: A Tool for SARS-CoV-2 Diagnosis, Monitoring New Strains and Phylodynamic Modeling in Molecular Epidemiology

Real-time reverse transcription-polymerase chain reaction assay panel for the detection of severe acute respiratory syndrome coronavirus 2 and its variants

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2

Evaluation of two RT-PCR screening assays for identifying SARS-CoV-2 variants

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

The evolution of rapid antigen detection systems and their application for COVID-19 and other serious respiratory infectious diseases

Coronavirus Disease 2019 (COVID-19) Diagnostic Tools: A Focus on Detection Technologies and Limitations. Curr Issues Mol Biol

Metropolitan wastewater analysis for COVID-19 epidemiological surveillance

Genomic surveillance to combat COVID-19: challenges and opportunities

COVID-19 dynamics after a national immunization program in Israel

Rapid Base-Specific Calling of SARS-CoV-2 Variants of Concern Using Combined RT-PCR Melting Curve Screening and SIRPH Technology. Open Forum Infect Dis

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom

Precision Response to the Rise of the SARS-CoV-2 B.1.1.7 Variant of Concern by Combining Novel PCR Assays and Genome Sequencing for Rapid Variant Detection and Surveillance. Microbiol Spectr

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera